Literature DB >> 27502281

MicroRNA-223-5p and -3p Cooperatively Suppress Necroptosis in Ischemic/Reperfused Hearts.

Dongze Qin1, Xiaohong Wang2, Yutian Li2, Liwang Yang2, Ruitao Wang3, Jiangtong Peng2, Kobina Essandoh2, Xingjiang Mu2, Tianqing Peng4, Qinghua Han5, Kai-Jiang Yu3, Guo-Chang Fan6.   

Abstract

Recent studies have shown that myocardial ischemia/reperfusion (I/R)-induced necrosis can be controlled by multiple genes. In this study, we observed that both strands (5p and 3p) of miR-223 were remarkably dysregulated in mouse hearts upon I/R. Precursor miR-223 (pre-miR-223) transgenic mouse hearts exhibited better recovery of contractile performance over reperfusion period and lesser degree of myocardial necrosis than wild type hearts upon ex vivo and in vivo myocardial ischemia. Conversely, pre-miR-223 knock-out (KO) mouse hearts displayed opposite effects. Furthermore, we found that the RIP1/RIP3/MLKL necroptotic pathway and inflammatory response were suppressed in transgenic hearts, whereas they were activated in pre-miR-223 KO hearts upon I/R compared with wild type controls. Accordingly, treatment of pre-miR-223 KO mice with necrostatin-1s, a potent necroptosis inhibitor, significantly decreased I/R-triggered cardiac necroptosis, infarction size, and dysfunction. Mechanistically, we identified two critical cell death receptors, TNFR1 and DR6, as direct targets of miR-223-5p, whereas miR-223-3p directly suppressed the expression of NLRP3 and IκB kinase α, two important mediators known to be involved in I/R-induced inflammation and cell necroptosis. Our findings indicate that miR-223-5p/-3p duplex works together and cooperatively inhibits I/R-induced cardiac necroptosis at multiple layers. Thus, pre-miR-223 may constitute a new therapeutic agent for the treatment of ischemic heart disease.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  inflammasome; ischemia; microRNA (miRNA); myocardial infarction; necrosis (necrotic death)

Mesh:

Substances:

Year:  2016        PMID: 27502281      PMCID: PMC5025706          DOI: 10.1074/jbc.M116.732735

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis.

Authors:  Ting Zhang; Yan Zhang; Mingyao Cui; Li Jin; Yimei Wang; Fengxiang Lv; Yuli Liu; Wen Zheng; Haibao Shang; Jun Zhang; Mao Zhang; Hongkun Wu; Jiaojiao Guo; Xiuqin Zhang; Xinli Hu; Chun-Mei Cao; Rui-Ping Xiao
Journal:  Nat Med       Date:  2016-01-04       Impact factor: 53.440

2.  Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis.

Authors:  Xiaohong Wang; Wei Huang; Yang Yang; Yigang Wang; Tianqing Peng; Jiang Chang; Charles C Caldwell; Basilia Zingarelli; Guo-Chang Fan
Journal:  Biochim Biophys Acta       Date:  2014-01-29

3.  Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo.

Authors:  Martinus I F J Oerlemans; Jia Liu; Fatih Arslan; Krista den Ouden; Ben J van Middelaar; Pieter A Doevendans; Joost P G Sluijter
Journal:  Basic Res Cardiol       Date:  2012-05-03       Impact factor: 17.165

Review 4.  Necroptosis and its role in inflammation.

Authors:  Manolis Pasparakis; Peter Vandenabeele
Journal:  Nature       Date:  2015-01-15       Impact factor: 49.962

5.  Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs.

Authors:  Stefan Koudstaal; Martinus I F J Oerlemans; Tycho I G Van der Spoel; Aafke W F Janssen; Imo E Hoefer; Pieter A Doevendans; Joost P G Sluijter; Steven A J Chamuleau
Journal:  Eur J Clin Invest       Date:  2015-01-13       Impact factor: 4.686

6.  Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse.

Authors:  Carlo Marchetti; Stefano Toldo; Jeremy Chojnacki; Eleonora Mezzaroma; Kai Liu; Fadi N Salloum; Andrea Nordio; Salvatore Carbone; Adolfo Gabriele Mauro; Anindita Das; Ankit A Zalavadia; Matthew S Halquist; Massimo Federici; Benjamin W Van Tassell; Shijun Zhang; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2015-07       Impact factor: 3.105

Review 7.  MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response.

Authors:  Kobina Essandoh; Yutian Li; Jiuzhou Huo; Guo-Chang Fan
Journal:  Shock       Date:  2016-08       Impact factor: 3.454

Review 8.  Regulated necrosis: disease relevance and therapeutic opportunities.

Authors:  Marcus Conrad; José Pedro Friedmann Angeli; Peter Vandenabeele; Brent R Stockwell
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

9.  Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model.

Authors:  Rabea Hinkel; Daniela Penzkofer; Stefanie Zühlke; Ariane Fischer; Wira Husada; Quan-Fu Xu; Elisabeth Baloch; Eva van Rooij; Andreas M Zeiher; Christian Kupatt; Stefanie Dimmeler
Journal:  Circulation       Date:  2013-07-29       Impact factor: 29.690

10.  E2F1-regulated miR-30b suppresses Cyclophilin D and protects heart from ischemia/reperfusion injury and necrotic cell death.

Authors:  K Wang; T An; L-Y Zhou; C-Y Liu; X-J Zhang; C Feng; P-F Li
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

View more
  44 in total

Review 1.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

Review 2.  miRNA-223 at the crossroads of inflammation and cancer.

Authors:  Jacob Jeffries; Wenqing Zhou; Alan Y Hsu; Qing Deng
Journal:  Cancer Lett       Date:  2019-03-13       Impact factor: 8.679

Review 3.  The Role of MicroRNAs in the Cardiac Response to Exercise.

Authors:  Xiaojun Liu; Colin Platt; Anthony Rosenzweig
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

Review 4.  Cardiovascular inflammation: RNA takes the lead.

Authors:  Colton R Martens; Shyam S Bansal; Federica Accornero
Journal:  J Mol Cell Cardiol       Date:  2019-03-14       Impact factor: 5.000

5.  Sinomenine Attenuates Cartilage Degeneration by Regulating miR-223-3p/NLRP3 Inflammasome Signaling.

Authors:  Hai-Chao Dong; Pei-Nan Li; Chang-Jian Chen; Xin Xu; Hong Zhang; Gang Liu; Lian-Jie Zheng; Peng Li
Journal:  Inflammation       Date:  2019-08       Impact factor: 4.092

6.  Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation.

Authors:  Bin Lu; Xu Gong; Zong-Qi Wang; Ye Ding; Chen Wang; Tian-Fei Luo; Mei-Hua Piao; Fan-Kai Meng; Guang-Fan Chi; Yi-Nan Luo; Peng-Fei Ge
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

7.  COP9 Signalosome Suppresses RIPK1-RIPK3-Mediated Cardiomyocyte Necroptosis in Mice.

Authors:  Peng Xiao; Changhua Wang; Jie Li; Huabo Su; Liuqing Yang; Penglong Wu; Megan T Lewno; Jinbao Liu; Xuejun Wang
Journal:  Circ Heart Fail       Date:  2020-06-24       Impact factor: 8.790

8.  Differentially expressed miRNAs in circulating exosomes between atrial fibrillation and sinus rhythm.

Authors:  Suyu Wang; Jie Min; Yue Yu; Liang Yin; Qing Wang; Hua Shen; Jie Yang; Peng Zhang; Jian Xiao; Zhinong Wang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

9.  Sectm1a deficiency aggravates inflammation-triggered cardiac dysfunction through disruption of LXRα signalling in macrophages.

Authors:  Yutian Li; Shan Deng; Xiaohong Wang; Wei Huang; Jing Chen; Nathan Robbins; Xingjiang Mu; Kobina Essandoh; Tianqing Peng; Anil G Jegga; Jack Rubinstein; David E Adams; Yigang Wang; Jiangtong Peng; Guo-Chang Fan
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

Review 10.  Cell type-specific microRNA therapies for myocardial infarction.

Authors:  Bohao Liu; Bryan Wang; Xiaokan Zhang; Roberta Lock; Trevor Nash; Gordana Vunjak-Novakovic
Journal:  Sci Transl Med       Date:  2021-02-10       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.